LianBio Eyes ‘Strategic Review’ As It Hands Camzyos Asia Rights Back To MyoKardia Parent BMS

 
• By Alaric DeArment
  
BMS is spending $350m for rights in China and other Asia-Pacific territories for Camzyos • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business